AMERICAN VANGUARD CORPORATION Key Metrics

2 years of history · ending 2024-12-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

M-Score (Beneish; >-1.78 flags risk)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Cash-Flow Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-5
Book Value Per Share
$8
Free Cash Flow Per Share
$0
Cash Per Share
Revenue Per Share
$20
OCF Per Share
$0
Return on Equity
-41.9%
Return on Assets
-18.0%
Return on Invested Capital
-18.0%
Debt to Equity
0.63
Current Ratio
1.63
Quick Ratio
0.86
Asset Turnover
0.78
Days Sales Outstanding
113.20
Days Payables Outstanding
59.12
Days Inventory On Hand
153.26
Cash Conversion Cycle
207.35
R&D / Revenue
6.0%
SBC / Revenue
0.8%
Working Capital
$147M
Net Current Asset Value
$-25M
Invested Capital
$380M
OCF / Net Income
-0.03
FCF / Net Income
-0.03
Accruals Ratio (Sloan)
-20.5%
Net Debt
$147M
Net Debt / EBITDA
-1.53
Interest Coverage
-6.14
Cash Coverage
0.24
Dividend Coverage
1.56
Tangible Common Equity
$63M
TCE / Total Assets
9.9%
Goodwill / Total Assets
3.1%
NOPAT
$-80M
Cash ROIC
0.9%
WC / Revenue
26.8%
Reinvestment Rate
5.1%
Total Payout Ratio
-2.0%
Asset Growth vs Revenue Growth
-11.5%
Revenue 5Y CAGR
3.2%
EPS 5Y CAGR
-20.8%
FCF 5Y CAGR
-16.4%
EBITDA 5Y CAGR
-12.4%
Book Value 5Y CAGR
-7.5%
Stock Price (FY-end)
$5
Market Cap
$130M
P/E Ratio
41.39
P/S Ratio
0.24
P/B Ratio
0.56
P/TB Ratio
2.06
P/OCF Ratio
33.12
P/FCF Ratio
33.12
Enterprise Value
$277M
EV / EBITDA
15.06
EV / Sales
0.51
EV / FCF
70.67
FCF Yield
3.0%
Dividend Yield
1.9%
Shareholder Yield
-1.5%
Buyback Yield
0.0%
R&D Yield
25.1%
Dividend Per Share
$0
DPS YoY Growth
-24.6%
Operating Leverage
8.61
Graham Number
$9
Shares Variation (YoY)
-10.6%
Beta (5Y)
0.98
Cost of Equity
9.4%
Cost of Debt (after tax)
8.9%
WACC
9.1%
ROIC - WACC Spread
-27.2%
52W High
$13
52W Low
$4
Trailing Return 1Y
-57.5%
Trailing Return 5Y
-75.4%
F-Score (Piotroski)
4.00
M-Score (Beneish)
-3.43
Z-Score (Altman)
1.25

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

AMERICAN VANGUARD CORPORATION — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes-0.20%
Foreign Rate Differential
Other Adjustments-0.60%
R&D Tax Credits0.40%
Valuation Allowance Change-11.60%
Effective Tax Rate-5.90%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$3.1M$8.2M$8.6M$2.8M$5.9M$2.7M
Income Taxes Paid (Cash)$3.9M$5.8M$20.0M$9.4M$8.8M$3.9M

AMERICAN VANGUARD CORPORATION — M&A AcquisitionsNEW

Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.

Agrinos Group Companies

Purchase-Price Allocation

Intangibles

$396.0K

Liabilities Assumed

$447.0K

Punto Verde Company

Purchase-Price Allocation

Liabilities Assumed

$447.0K